Early results of dexamethasone implant ranibizumab and triamcinolone in macular edema due to branch retinal vein occlusion
Yazarlar (3)
Erhan Yumusak Kirikkale Üniversitesi, Türkiye
Nesrin Buyuktortop Kirikkale Üniversitesi, Türkiye
Prof. Dr. Kemal ÖRNEK Kirikkale Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | European Journal of Ophthalmology | ||
| Dergi ISSN | 1120-6721 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2016 |
| Kabul Tarihi | 12-04-2026 | Yayınlanma Tarihi | – |
| Cilt / Sayı / Sayfa | 26 / 1 / 54–59 | DOI | 10.5301/ejo.5000637 |
| Özet |
| PurposeTo compare the short-term results of the efficacy and safety of dexamethasone intravitreal implant (DEX), ranibizumab (RAN), and intravitreal triamcinolone acetonide (IVTA) in macular edema secondary to branch retinal vein occlusion (BRVO).MethodsOne eye each of 32 patients who were treated with intravitreal injections for macular edema secondary to BRVO was studied. This retrospective study included 3 groups. The patients received DEX in group 1 (n = 11), RAN in group 2 (n = 11), and IVTA in group 3 (n = 10). Data were collected before and after the injections at the first and third months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were analyzed statistically.ResultsThe median duration of the follow-up was 3.0 months in overall groups. The BCVA increased significantly in all groups (p = 0.018, p = 0.034, p = 0.014, respectively). The CMT … |
| Anahtar Kelimeler |
| Branch retinal vein occlusion | Dexamethasone intravitreal implant | Macular edema | Ranibizumab | Triamcinolone |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 29 |
| Web of Science | 10 |